Fairvoy Private Wealth LLC Sells 394 Shares of AstraZeneca PLC $AZN

Fairvoy Private Wealth LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 8.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,529 shares of the company’s stock after selling 394 shares during the period. Fairvoy Private Wealth LLC’s holdings in AstraZeneca were worth $316,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Dynamic Advisor Solutions LLC raised its stake in shares of AstraZeneca by 58.4% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company’s stock worth $960,000 after purchasing an additional 4,811 shares in the last quarter. SCS Capital Management LLC bought a new stake in shares of AstraZeneca during the 1st quarter worth approximately $3,066,000. Robbins Farley bought a new stake in AstraZeneca in the 2nd quarter valued at $1,857,000. Farther Finance Advisors LLC raised its stake in AstraZeneca by 13.1% in the 1st quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company’s stock valued at $442,000 after acquiring an additional 706 shares during the period. Finally, Oliver Luxxe Assets LLC raised its stake in AstraZeneca by 6.0% in the 2nd quarter. Oliver Luxxe Assets LLC now owns 78,301 shares of the company’s stock valued at $5,472,000 after acquiring an additional 4,449 shares during the period. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of NASDAQ AZN opened at $85.31 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The stock’s fifty day moving average price is $78.04 and its two-hundred day moving average price is $73.10. AstraZeneca PLC has a one year low of $61.24 and a one year high of $85.50. The firm has a market cap of $264.58 billion, a price-to-earnings ratio of 32.07, a P/E/G ratio of 1.54 and a beta of 0.36.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.08 billion. During the same period in the prior year, the firm posted $1.24 EPS. The company’s revenue for the quarter was up 16.1% on a year-over-year basis. On average, equities analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were issued a $0.505 dividend. This represents a yield of 200.0%. The ex-dividend date of this dividend was Friday, August 8th. AstraZeneca’s dividend payout ratio is currently 37.97%.

Analysts Set New Price Targets

AZN has been the topic of a number of research analyst reports. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research note on Saturday, September 27th. Berenberg Bank set a $97.00 price target on AstraZeneca in a research note on Wednesday, July 9th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.